Stifel 2021 Virtual Healthcare Conference on November 15, 2021 at 11:20 am ET
Jefferies London Healthcare Conference November 17, 2021 at 12:20 pm GMT
4th Annual Evercore ISI HealthCONx Virtual Conference on November 30, 2021 at 4:20 pm ET
Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced its participation in the Stifel 2021 Virtual Healthcare Conference, Jefferies London Healthcare Conference, and the 4th Annual Evercore ISI HealthCONx Virtual Conference.
Conference Details: |
||
Event: |
|
Stifel 2021 Virtual Healthcare Conference |
Date: |
|
November 15, 2021 |
Time: |
|
11:20 am ET |
Format: |
|
Fireside Chat |
Participants: |
|
RA Session II, President, Founder and Chief Executive Officer |
|
|
Dr. Suyash Prasad, Chief Medical Officer and Head of R&D |
|
|
Kamran Alam, Chief Financial Officer |
|
|
Dr. Kimberly Lee, SVP, Corporate Communications and Investor Relations |
|
|
|
Event: |
|
Jefferies London Healthcare Conference |
Date: |
|
November 17, 2021 |
Time: |
|
12:20 pm GMT |
Format: |
|
Fireside Chat |
Participant: |
|
RA Session II, President, Founder and Chief Executive Officer |
|
|
Dr. Suyash Prasad, Chief Medical Officer and Head of R&D |
|
|
Kamran Alam, Chief Financial Officer |
|
|
Dr. Kimberly Lee, SVP, Corporate Communications and Investor Relations |
|
|
|
Event: |
|
4th Annual Evercore ISI HealthCONx Virtual Conference |
Date: |
|
November 30, 2021 |
Time: |
|
4:20 pm ET |
Format: |
|
Fireside Chat |
Participant: |
|
RA Session II, President, Founder and Chief Executive Officer |
|
|
Dr. Suyash Prasad, Chief Medical Officer and Head of R&D |
|
|
Kamran Alam, Chief Financial Officer |
|
|
Dr. Kimberly Lee, SVP, Corporate Communications and Investor Relations |
About Taysha Gene Therapies
Taysha Gene Therapies (Nasdaq: TSHA) is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, we aim to rapidly translate our treatments from bench to bedside. We have combined our team’s proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program to build an extensive, AAV gene therapy pipeline focused on both rare and large-market indications. Together, we leverage our fully integrated platform—an engine for potential new cures—with a goal of dramatically improving patients’ lives. More information is available at www.tayshagtx.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211108005219/en/
Contacts
Company Contact:
Kimberly Lee, D.O.
SVP, Corporate Communications and Investor Relations
Taysha Gene Therapies
klee@tayshagtx.com
Media Contact:
Carolyn Hawley
Canale Communications
carolyn.hawley@canalecomm.com
